Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation

Medicine and Dentistry

• Acute Graft Rejection 9%
• Allograft Vasculopathy 9%
• Antibody 9%
• Atheroma 27%
• B Cell 27%
• Cardiac Allograft Vasculopathy 18%
• CD20 9%
• Cell Population 9%
• Clinical Trial 18%
• Combination Therapy 27%
• Coronary Artery 9%
• Depletion 9%
• Development 9%
• Differentiation 9%
• Donor 9%
• Follow up 9%
• Heart Graft 9%
• Heart Transplantation 18%
• HLA Antibody 9%
• Intravascular Ultrasound 18%
• Mortality 18%
• Organ Transplantation 9%
• Placebo 63%
• Posttransplant Lymphoproliferative Disease 9%
• Rituximab 100%
• Transplantation 9%